Analyse af alle dødsårsager viste ingen signifikant forskel mellem prasugrel og clopidogrel i den totale AKS- population (2, 76% mod 2, 90%), i UA/ NSTEMI - populationen (2. 58% mod 2. 41%) og i STEMI- populationen (3. 28% vs 4. 31%).
Analysis of all cause death did not show any significant difference between prasugrel and clopidogrel in the All ACS population (2.76% vs 2.90%), in the UA/ NSTEMI population (2.58% vs 2.41%), and in the STEMI population (3.28% vs 4.31%).